Compare IDEXX Laboratories, Inc. (IDXX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Verizon Communications Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Verizon Communications Inc trades at $41.83 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 4.8× IDEXX Laboratories, Inc.'s market cap, and Verizon Communications Inc pays a 6.11% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Verizon Communications Inc for 109 Days on average.
| IDXX | VZ | |
|---|---|---|
Market Cap | $40.43B | $192.57B |
Volume | 692,164 | 20,940,094 |
Sector | Health | Media |
52-Week High | $766.68 | $51.45 |
52-Week Low | $504.70 | $38.40 |
Typical Hold Time | 46 Days | 109 Days |
Enterprise Value | $41.32B | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Verizon (VZ) trades at $41.65, down 9% today, with bearish technical signals but solid fundamentals. The stock shows consistent earnings beats (Q4 2025-Q2 2026) and maintains strong cash flow ($37.1B operating cash flow in 2025). Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand coverage and the election of Charles Phillips to the board (GlobeNewsWire, September 29, 2026).
Outlook: Attractive for income investors with a 6.8% dividend yield and stable cash flow, but high debt ($144B total debt) and competitive pressures pose risks. Analyst consensus price target of $48.17 suggests 16% upside, though technical indicators remain bearish near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
